Aminoacyl-tRNA synthetases are ubiquitously expressed proteins that charge tRNAs with their cognate amino acids. By ensuring the fidelity of protein synthesis, these enzymes are essential for the viability of every cell. Yet, mutations in six tRNA synthetases specifically affect the peripheral nerves and cause Charcot-MarieTooth (CMT) disease. The CMT-causing mutations in tyrosyl-and glycyl-tRNA synthetases (YARS and GARS, respectively) alter the activity of the proteins in a range of ways (some mutations do not impact charging function, while others abrogate it), making a loss of function in tRNA charging unlikely to be the cause of disease pathology. It is currently unknown which cellular mechanisms are triggered by the mutant enzymes and how this leads to neurodegeneration. Here, by expressing two pathogenic mutations (G240R, P234KY) in Drosophila, we generated a model for GARS-associated neuropathy. We observed compromised viability, and behavioral, electrophysiological and morphological impairment in flies expressing the cytoplasmic isoform of mutant GARS. Their features recapitulated several hallmarks of CMT pathophysiology and were similar to the phenotypes identified in our previously described Drosophila model of YARS-associated neuropathy. Furthermore, CG8316 and CG15599 -genes identified in a retinal degeneration screen to modify mutant YARS, also modified the mutant GARS phenotypes. Our study presents genetic evidence for common mutant-specific interactions between two CMTassociated aminoacyl-tRNA synthetases, lending support for a shared mechanism responsible for the synthetase-induced peripheral neuropathies.
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Introduction
Charcot-Marie-Tooth (CMT) disease, or hereditary motor and sensory neuropathy, is the most common human inherited neuromuscular disorder affecting specifically the peripheral nerves. CMT symptoms include progressive motor impairment, distal muscle weakness and wasting, sensory loss and skeletal deformities. Based on electrophysiological and neuropathological criteria, the disease is classified into demyelinating forms (CMT1), axonal forms (CMT2), and intermediate forms combining features of CMT1 and CMT2 (Pareyson and Marchesi, 2009) . There is no cure for any of these CMT phenotypes, posing substantial personal, social and economic burden. Mutations in over 40 genes are known to cause CMT, making it an extremely genetically heterogeneous disorder (http://www.molgen.vib-ua.be/CMTMutations/). Notably, the known gene products do not represent a single functional category, but range from molecules regulating and establishing the myelin component of the peripheral nervous system (PNS) to ubiquitously expressed proteins. Intriguingly, genetic defects in six aminoacyl-tRNA synthetases (aaRSs) -GARS (Antonellis et al., 2003) , YARS (Jordanova 
